SAID M Afify
Lecturer of Medical Biochemistry with focusing on cancer biology, at Divsion of biochemistry, Faculty of Science , Menofiua University, Egypt.
Currently working at Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan . Our project is focusing on the generation of cancer stem cells from pluripotent stem cells
Currently working at Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan . Our project is focusing on the generation of cancer stem cells from pluripotent stem cells
less
Interests
Uploads
Papers by SAID M Afify
Methods: This study was carried out on eighty-eight patients infected with HCV and twenty healthy subjects as a control. Complete blood count (CBC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), antiHCV antibody, detection of HCV RNA by real-time PCR, and serum ferritin (SF) were assessed. Then API, ARR, APRI, FIB-4, and Fibro-Q were calculated. Different fibrosis stages (mild fibrosis stage (F1), moderate fibrosis stage (F2), severe fibrosis stage (F3), cirrhotic stage (F4)) were assessed using transient elastography by Fibro Scan®.
Results: FIB-4 index was significantly elevated (p < 0.01) with the progression of liver fibrosis at F1, F2, F3, and F4 when compared to healthy control group. The APRI score elevation between F0 and F3 and between F0 and F4 was significant (p < 0.01). SF was elevated in all fibrosis stages and significantly (p < 0.01) at F3 and F4 compared to controls.
Conclusions: APRI coupled with SF should be the best reliable biomarkers for liver cirrhosis. Simultaneously, from our data SF involved in all stages of inflammation. Therefore, down regulation of ferritin in the early stage of fibrosis should be helpful in decreasing the inflammatory effect of ferritin.
as for evidence of antiviral treatment. This study was designed to investigate whether the serum iron indices is a conceivable mean
for determination of liver fibroses stage. Hepatitis C virus (HCV) infected untreated patients (n=88) were admitted mainly for
evaluation of HCV infection. Twenty healthy individuals negative for HCV disease were included in this study as a control group. All
infected subjects had active HCV confirmed by real time PCR, liver fibrosis stages was appreciated using transient hepatic
elastography (TE) by Fibro Scan, the activities of serum liver function biomarker enzymes and iron indices were determined by
automated analyser. Concentration of serum ferritin was increased with the evolution of fibrosis in all stages from F0 to F4 and this
increase was significant (P<0.01) in cirrhotic patients (F4). There was a positive high correlation between serum level of ferritin and
progression of fibrosis (0.983911) (R2= 0.968). Transferrin concentration was significantly elevated (P<0.01) with the progression of
fibrosis (F1-F4). There was a significant positive correlation between serum concentration of transferrin and progression of fibrosis
(P<0.05) and this correlation was highly positive from stage 0 (F0) to stage 2 (F2) (0.976) (R2=0.953). Serum transferrin
concentration may be used as liver fibrosis biomarker in the early stages of fibrosis. Serum ferritin concentration may be used as
liver fibrosis biomarkers especially for end stage fibrosis.
Keywords: Liver fibrosis biomarkers, Ferritin, Transferrin, HCV.
Methods: This study was carried out on eighty-eight patients infected with HCV and twenty healthy subjects as a control. Complete blood count (CBC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), antiHCV antibody, detection of HCV RNA by real-time PCR, and serum ferritin (SF) were assessed. Then API, ARR, APRI, FIB-4, and Fibro-Q were calculated. Different fibrosis stages (mild fibrosis stage (F1), moderate fibrosis stage (F2), severe fibrosis stage (F3), cirrhotic stage (F4)) were assessed using transient elastography by Fibro Scan®.
Results: FIB-4 index was significantly elevated (p < 0.01) with the progression of liver fibrosis at F1, F2, F3, and F4 when compared to healthy control group. The APRI score elevation between F0 and F3 and between F0 and F4 was significant (p < 0.01). SF was elevated in all fibrosis stages and significantly (p < 0.01) at F3 and F4 compared to controls.
Conclusions: APRI coupled with SF should be the best reliable biomarkers for liver cirrhosis. Simultaneously, from our data SF involved in all stages of inflammation. Therefore, down regulation of ferritin in the early stage of fibrosis should be helpful in decreasing the inflammatory effect of ferritin.
as for evidence of antiviral treatment. This study was designed to investigate whether the serum iron indices is a conceivable mean
for determination of liver fibroses stage. Hepatitis C virus (HCV) infected untreated patients (n=88) were admitted mainly for
evaluation of HCV infection. Twenty healthy individuals negative for HCV disease were included in this study as a control group. All
infected subjects had active HCV confirmed by real time PCR, liver fibrosis stages was appreciated using transient hepatic
elastography (TE) by Fibro Scan, the activities of serum liver function biomarker enzymes and iron indices were determined by
automated analyser. Concentration of serum ferritin was increased with the evolution of fibrosis in all stages from F0 to F4 and this
increase was significant (P<0.01) in cirrhotic patients (F4). There was a positive high correlation between serum level of ferritin and
progression of fibrosis (0.983911) (R2= 0.968). Transferrin concentration was significantly elevated (P<0.01) with the progression of
fibrosis (F1-F4). There was a significant positive correlation between serum concentration of transferrin and progression of fibrosis
(P<0.05) and this correlation was highly positive from stage 0 (F0) to stage 2 (F2) (0.976) (R2=0.953). Serum transferrin
concentration may be used as liver fibrosis biomarker in the early stages of fibrosis. Serum ferritin concentration may be used as
liver fibrosis biomarkers especially for end stage fibrosis.
Keywords: Liver fibrosis biomarkers, Ferritin, Transferrin, HCV.